<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974751</url>
  </required_header>
  <id_info>
    <org_study_id>TP0118</org_study_id>
    <nct_id>NCT02974751</nct_id>
  </id_info>
  <brief_title>Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue</brief_title>
  <acronym>OPEN WATER</acronym>
  <official_title>Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PROCEPT BioRobotics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PROCEPT BioRobotics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the AQUABEAM System for the
      treatment of Lower Urinary Tract Symptoms (LUTS) resulting from Benign Prostatic Hyperplasia
      (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>IPSS score change</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">178</enrollment>
  <condition>BPH</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aquablation</intervention_name>
    <description>Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with lower urinary tract symptoms, including those with urinary retention, who
        meet all other enrollment criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male.

          -  Subject has diagnosis of lower urinary tract symptoms due to benign prostatic
             enlargement causing bladder outlet obstruction or in urinary retention.

          -  Prostate size ≥ 20 mL and ≤ 150 mL as measure by TRUS.

          -  Patient is mentally capable and willing to sign a study-specific informed consent
             form.

        Exclusion Criteria:

          -  Patients unable to stop anticoagulants, antiplatelet agents, or non-steroidal
             anti-inflammatory agents (NSAIDs, including aspirin greater or equal to 100mg) prior
             to treatment per standard of care.

          -  History of gross haematuria.

          -  Participants using systemic immune-suppressants including corticosteroids (except
             inhalants), known coagulopathy, or platelet disorder (except aspirin below 100mg/d).

          -  Contraindication to both general and spinal anesthesia.

          -  Any severe illness that would prevent complete study participation or confound study
             results.

          -  Subject is unwilling to accept a transfusion should one be required.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinikum Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauranga Urology Research</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Lebanon</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aquablation</keyword>
  <keyword>AQUABEAM</keyword>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

